Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orlistat for nonalcoholic fatty liver disease
ChiCTR-IPR-17012258Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of orlistat in metabolic dysfunction-associated steatotic liver disease (MASLD) (2 arms), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoints: Hepatic fat fraction, Liver pathology and 3 more. Planned start Sep 2017; status: not yet recruiting.
02
Drugs
orlistat
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on ChiCTR-IPR-17012258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17012258.